{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:40:30Z","timestamp":1790872830372,"version":"4.1.0"},"reference-count":52,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: BRAF mutations are found in 10% of colon cancers (CCs) and are associated with poor prognosis in metastatic disease. BRAF V600E predicts sensitivity to cetuximab + encorafenib in the metastatic setting. With new trials testing encorafenib-containing regimens for early-stage CC, we sought to characterize the clinical outcomes of early-stage BRAF V600E CC. Methods: We performed a systematic review and meta-analysis. Key inclusion criteria were a diagnosis of stage 2\/3 BRAF V600E CC. Co-primary endpoints were overall survival (OS) and recurrence\/disease-free survival (DFS). Meta-analysis was performed with a random-effects model incorporating sample size, hazard ratio (HR), and 95% confidence intervals (CIs). Results: A total of 206 studies underwent full-text review. Of these, six randomized controlled trials were included, comprising 6836 and 843 patients with wild-type (WT) and BRAF V600E, respectively. BRAF V600E was associated with inferior OS (HR 1.49, CI 1.21\u20131.75) and DFS (HR 1.17, CI 1.03\u20131.33). This finding remains in patients with microsatellite instability\u2014low\/stable or proficient mismatch repair (OS: HR 1.66, CI 1.36\u20132.02, DFS: HR 1.45, CI 1.22\u20131.72). Conclusions: BRAF V600E is associated with inferior prognoses compared to BRAF WT in early-stage CC. This finding will help optimize trial design for this population.<\/jats:p>","DOI":"10.3390\/curroncol32110624","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:56:45Z","timestamp":1762513005000},"page":"624","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4869-5895","authenticated-orcid":false,"given":"Matthew","family":"Dankner","sequence":"first","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"Rosalind and Morris Goodman Cancer Institute, Montreal, QC H3T 1E2, Canada"},{"name":"Lady Davis Institute for Medical Research & Segal Cancer Centre, Jewish General Hospital, Montr\u00e9al, QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie-Rose","family":"Dub\u00e9","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sorin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"Rosalind and Morris Goodman Cancer Institute, Montreal, QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J. B.","family":"Stein","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3503-5281","authenticated-orcid":false,"given":"Alexander","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"Rosalind and Morris Goodman Cancer Institute, Montreal, QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsu Lawrence","family":"Park","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"Gerald Bronfman Department of Oncology, McGill University, Montr\u00e9al, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0124-7323","authenticated-orcid":false,"given":"Jamie","family":"Magrill","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"Rosalind and Morris Goodman Cancer Institute, Montreal, QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-7159","authenticated-orcid":false,"given":"Anna-Maria","family":"Lazaratos","sequence":"additional","affiliation":[{"name":"Rosalind and Morris Goodman Cancer Institute, Montreal, QC H3T 1E2, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3C 3J7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4123-0051","authenticated-orcid":false,"given":"Joan Miguel","family":"Romero","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"Rosalind and Morris Goodman Cancer Institute, Montreal, QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Batist","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"Lady Davis Institute for Medical Research & Segal Cancer Centre, Jewish General Hospital, Montr\u00e9al, QC H3T 1E2, Canada"},{"name":"Gerald Bronfman Department of Oncology, McGill University, Montr\u00e9al, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kavan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"Lady Davis Institute for Medical Research & Segal Cancer Centre, Jewish General Hospital, Montr\u00e9al, QC H3T 1E2, Canada"},{"name":"Gerald Bronfman Department of Oncology, McGill University, Montr\u00e9al, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April A. N.","family":"Rose","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"Lady Davis Institute for Medical Research & Segal Cancer Centre, Jewish General Hospital, Montr\u00e9al, QC H3T 1E2, Canada"},{"name":"Gerald Bronfman Department of Oncology, McGill University, Montr\u00e9al, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Ma","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"Gerald Bronfman Department of Oncology, McGill University, Montr\u00e9al, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: New rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kazandjian, S., Rousselle, E., Dankner, M., Cescon, D.W., Spreafico, A., Ma, K., Kavan, P., Batist, G., and Rose, A.A.N. (2024). The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers. Cancers, 16.","DOI":"10.3390\/cancers16020445"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00195","article-title":"Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology","volume":"2","author":"Dankner","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2200107","DOI":"10.1200\/PO.22.00107","article-title":"Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors","volume":"6","author":"Dankner","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1200\/JCO.2016.71.4394","article-title":"(Non-V600) BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer","volume":"35","author":"Jones","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-14-2779","article-title":"Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients","volume":"21","author":"Yaeger","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.20.01994","article-title":"Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.22.01693","article-title":"ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer","volume":"41","author":"Taieb","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: A randomized phase 3 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.2217\/fon-2022-0949","article-title":"TRESBIEN (OGSG 2101): Encorafenib, binimetinib and cetuximab for early recurrent stage II\/III BRAF V600E-mutated colorectal cancer","volume":"18","author":"Boku","year":"2022","journal-title":"Future Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"TPS3641","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3641","article-title":"A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II\/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004","volume":"41","author":"Yaeger","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ciappina, G., Toscano, E., Ottaiano, A., Capuozzo, M., Consolo, P., Maiorana, E., Carroccio, P., Franchina, T., Ieni, A., and Di Mauro, A. (2025). Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26052216"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/cncr.28729","article-title":"BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer","volume":"120","author":"Yaeger","year":"2014","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1200\/JCO.2009.22.4295","article-title":"KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial","volume":"27","author":"Richman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_26","first-page":"660","article-title":"BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: Clinical characteristics, clinical behavior, and response to targeted therapies","volume":"6","author":"Clarke","year":"2015","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.5225","article-title":"Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial","volume":"2","author":"Taieb","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","article-title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","volume":"28","author":"Roth","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study","volume":"33","author":"Vernerey","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_31","first-page":"68","article-title":"Product Review: Covidence (Systematic Review Software)","volume":"35","author":"Babineau","year":"2014","journal-title":"J. Can. Health Libr. Assoc.\/J. L\u2019association Biblioth\u00e8ques Sant\u00e9 Can."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: A practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.breast.2023.04.008","article-title":"Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases","volume":"69","author":"Lazaratos","year":"2023","journal-title":"Breast"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1158\/1078-0432.CCR-15-0527","article-title":"Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)","volume":"21","author":"Sinicrope","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2013.48.9591","article-title":"Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy","volume":"31","author":"Sinicrope","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-11-2246","article-title":"Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803","volume":"18","author":"Ogino","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1158\/1078-0432.CCR-07-1489","article-title":"Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer","volume":"14","author":"French","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.4143\/crt.2019.008","article-title":"Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer","volume":"51","author":"Sfakianaki","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12029-021-00675-1","article-title":"Prognostic Factors for Survival in Transverse Colon Cancers","volume":"53","year":"2022","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hu, H., Wu, Z., Wang, C., Huang, Y., Zhang, J., Cai, Y., Xie, X., Li, J., Shen, C., and Li, W. (2020). Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.579478"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1158\/1078-0432.CCR-12-0605","article-title":"Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment of their prognostic and oxaliplatin predictive value","volume":"18","author":"Gavin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1200\/JCO.2010.30.1366","article-title":"Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer","volume":"29","author":"Hutchins","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S2468-1253(18)30117-1","article-title":"Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: Results from the QUASAR 2 clinical trial and an Australian community-based series","volume":"3","author":"Domingo","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/jnci\/djab190","article-title":"KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis","volume":"114","author":"Formica","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zhu, L., Dong, C., Cao, Y., Fang, X., Zhong, C., Li, D., and Yuan, Y. (2016). Prognostic Role of BRAF Mutation in Stage II\/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154795"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Pentheroudakis, G., Raptou, G., Kotoula, V., Wirtz, R.M., Vrettou, E., Karavasilis, V., Gourgioti, G., Gakou, C., Syrigos, K.N., and Bournakis, E. (2015). Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: A prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124612"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Tabernero","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Shiu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fon-2022-1249","article-title":"SEAMARK: Phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H\/dMMR BRAFV600E-mutant mCRC","volume":"20","author":"Elez","year":"2023","journal-title":"Future Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/11\/624\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T05:27:41Z","timestamp":1762579661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/11\/624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["curroncol32110624"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32110624","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}